1098. A Phase 1 Safety and Tolerability of Single Ascending Doses of a Novel Engineered Cationic Peptide, PLG0206, in Healthy Subjects

BACKGROUND: PLG0206 is a novel engineered cationic antimicrobial peptide being evaluated for treatment of prosthetic joint infections (PJI). This abstract presents the results from the first in human study to evaluate the safety, tolerability and pharmacokinetic (PK) profile of PLG0206 when administ...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, David, Dobbins, Despina, Ghahramani, Parviz, Steckbeck, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644641/
http://dx.doi.org/10.1093/ofid/ofab466.1292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644641/
http://dx.doi.org/10.1093/ofid/ofab466.1292

Ejemplares similares